ライフサイエンスコーパス: pandemic influenza

1 jor threat to human health and the source of pandemic influenza.

2 to reduce the impact of epidemic as well as pandemic influenza.

3 can have dramatic effects on transmission of pandemic influenza.

4 that can shed light on the latent period of pandemic influenza.

5 icant epidemiological impact on seasonal and pandemic influenza.

6 tiviral drug treatment during an outbreak of pandemic influenza.

7 morbidity and mortality during seasonal and pandemic influenza.

8 es vulnerable to a third, wintertime wave of pandemic influenza.

9 of otitis media, and antiviral treatment of pandemic influenza.

10 predictors of both seasonal and potentially pandemic influenza.

11 provide a rapid response platform to control pandemic influenza.

12 Pandemic influenza A (H1N1) 2009 (pandemic H1N1) is spre

13 ates had been associated with confirmed 2009 pandemic influenza A (H1N1) [2009 H1N1] virus infection.

14 respond to the first and subsequent years of pandemic influenza A (H1N1) circulation.

15 f 17,855 probable or confirmed cases of 2009 pandemic influenza A (H1N1) had been reported in the Uni

16 The 2009 pandemic influenza A (H1N1) has been recognized to cause

17 for morbidity and mortality related to 2009 pandemic influenza A (H1N1) infection.

18 revious epidemic and pandemic diseases, 2009 pandemic influenza A (H1N1) may pose an increased risk o

19 Since the introduction of pandemic influenza A (H1N1) to the USA in 2009, the Infl

20 ated in Maine before or concurrent with 2009 pandemic influenza A (H1N1) virus (pH1N1) peak activity.

21 , an outbreak due to infection with the 2009 pandemic influenza A (H1N1) virus (pH1N1) was investigat

22 During the spring of 2009, a pandemic influenza A (H1N1) virus emerged and spread glo

23 The 2009 pandemic influenza A (H1N1) virus exhibits hemagglutinin

24 A new pandemic influenza A (H1N1) virus has emerged, causing i

25 spiratory viral panel (RVP) results for 2009 pandemic influenza A (H1N1) virus specimens.

26 osition 222 in the hemagglutinin of the 2009 pandemic influenza A (H1N1) virus was developed.

27 nosuppressed patients infected with the 2009 pandemic influenza A (H1N1) virus within a few days afte

28 re prominent features of infection with 2009 pandemic influenza A (H1N1) virus.

29 Oseltamivir resistance among 2009 pandemic influenza A (H1N1) viruses (pH1N1) is rare.

30 yped for seasonal A/H1, A/H3, A/H5, and 2009 pandemic influenza A (pH1N1).

31 Following detection of pandemic influenza A H1N1 (pH1N1) in Dallas/Fort Worth,

32 Molecular evolutionary analyses of the 2009 pandemic influenza A H1N1 [A(H1N1)pdm09] virus revealed

33 cation among hospitalized patients with 2009 pandemic influenza A H1N1 [pH1N1] in the United States i

34 Even though the majority of cases of 2009 pandemic influenza A H1N1 are mild, severe disease does

35 he role of seasonal influenza vaccination in pandemic influenza A H1N1 disease is important to addres

36 The majority of cases of 2009 pandemic influenza A H1N1 in children have been mild.

37 ical presentations, and outcomes of the 2009 pandemic influenza A H1N1 in children.

38 All paediatric deaths related to pandemic influenza A H1N1 infection from June 26, 2009,

39 itted for at least 12 hr with a diagnosis of pandemic influenza A H1N1 infection in a single hospital

40 Clinical and epidemiological data of pandemic influenza A H1N1 infection in solid-organ trans

41 disease mortality rates associated with 2009 pandemic influenza A H1N1 infection with the ratio of ex

42 rs) have been disproportionately affected by pandemic influenza A H1N1 infection.

43 ory mortality rates associated with the 2009 pandemic influenza A H1N1 strain by age (0-17 years, 18-

44 from, and incidence of infection with, 2009 pandemic influenza A H1N1 virus is essential for modelli

45 ovascular mortality associated with the 2009 pandemic influenza A H1N1 was 15 times higher than repor

46 ascular mortality rates associated with 2009 pandemic influenza A H1N1 were multiplied by age to calc

47 boratory-confirmed deaths caused by the 2009 pandemic influenza A H1N1 were reported worldwide for th

48 70 paediatric deaths related to pandemic influenza A H1N1 were reported.

49 infected with novel viruses such as the 2009 pandemic influenza A H1N1, avian influenza A H5N1 virus

50 deaths (46,000-179,900) associated with 2009 pandemic influenza A H1N1.

51 ue number of the deaths associated with 2009 pandemic influenza A H1N1.

52 laboratory confirmed or clinically diagnosed pandemic influenza A H1N1pdm09 virus infection.

53 tality in patients admitted to hospital with pandemic influenza A H1N1pdm09 virus infection.

54 ships in ferrets infected with the 2009 H1N1 pandemic influenza A virus (H1N1pdm virus).

55 Seasonal and pandemic influenza A virus (IAV) continues to be a publi

56 rs to devise host-targeted therapies against pandemic influenza A virus (IAV) led us to investigate t

57 ng, and geographical origin of the 1918-1920 pandemic influenza A virus have remained tenaciously obs

58 To understand 2009 pandemic influenza A virus subtype H1N1 (A[H1N1]pdm09) c

59 Following the emergence of 2009 pandemic influenza A virus subtype H1N1 (A[H1N1]pdm09) i

60 We documented the introduction of 2009 pandemic influenza A virus subtype H1N1 (A[H1N1]pdm09) i

61 The emergence of swine-origin 2009 pandemic influenza A virus subtype H1N1 (A[H1N1]pdm09) p

62 circulating influenza A virus subtype; 2009 pandemic influenza A virus subtype H1N1 (A[H1N1]pdm09) r

63 de vaccination against infection due to 2009 pandemic influenza A virus subtype H1N1 (A[H1N1]pdm09) t

64 e induced by the monovalent inactivated 2009 pandemic influenza A virus subtype H1N1 (A[H1N1]pdm09) v

65 The 2009 pandemic influenza A virus subtype H1N1 (A[H1N1]pdm09) w

66 positive for influenza virus, including 2009 pandemic influenza A virus subtype H1N1 (A[H1N1]pdm09; n

67 ealthy pregnant women and cultured with 2009 pandemic influenza A virus subtype H1N1 (H1N1/09).

68 increased risk for serious outcomes of 2009 pandemic influenza A virus subtype H1N1 (influenza A[H1N

69 ata about respiratory coinfections with 2009 pandemic influenza A virus subtype H1N1 during the 2009-

70 A virus subtype H3N2 predominated, and 2009 pandemic influenza A virus subtype H1N1 had little impac

71 In 2009, pandemic influenza A virus subtype H1N1 was detected in

72 ntly, mortality has emerged as an outcome of pandemic influenza A virus subtype H1N1, necessitating d

73 ality, of which 9 studied patients with 2009 pandemic influenza A virus subtype H1N1.

74 The risk of emerging pandemic influenza A viruses (IAVs) that approach the de

75 The emergence of new pandemic influenza A viruses requires overcoming barrier

76 Pandemic influenza A viruses that emerge from animal res

77 a mixing vessel for the generation of novel pandemic influenza A viruses through reassortment becaus

78 There were 23 cases of confirmed 2009 pandemic influenza A(H1N1) (A[H1N1]pdm09) infection for

79 The 2009 pandemic influenza A(H1N1) (A[H1N1]pdm09) vaccine compon

80 asonal influenza (during 2003-2009) and 2009 pandemic influenza A(H1N1) (during 2009-2010).

81 d with seasonal influenza (n = 5270) or 2009 pandemic influenza A(H1N1) (H1N1pdm09; n = 4962).

82 eexisting antibodies to the hemagglutinin of pandemic influenza A(H1N1) 2009 (hereafter pandemic H1N1

83 person transmission of oseltamivir-resistant pandemic influenza A(H1N1) 2009 virus that occurred in a

84 eceptor-binding site of the hemagglutinin of pandemic influenza A(H1N1) 2009 viruses have been detect

85 After 2009, pandemic influenza A(H1N1) [A(H1N1)pdm09] cocirculated w

86 onfidence interval [CI], 2.61-6.13) for 2009 pandemic influenza A(H1N1) and 1.76 (95% CI, 1.33-2.32)

87 Seasonal TIV prevented pandemic influenza A(H1N1) and influenza B infections in

88 Pandemic influenza A(H1N1) emerged rapidly in California

89 of 2009 may have triggered the fall wave of pandemic influenza A(H1N1) in the United States.

90 who received TIV also a had reduced risk of pandemic influenza A(H1N1) indicated by serology, with a

91 a from 683 critically ill patients with 2009 pandemic influenza A(H1N1) infection admitted to 35 inte

92 918 influenza pandemic and up to 34% of 2009 pandemic influenza A(H1N1) infections managed in intensi

93 seasonal influenza vaccination against 2009 pandemic influenza A(H1N1) remains unclear.

94 emic resurgence of influenza due to the 2009 pandemic influenza A(H1N1) strain (A[H1N1]pdm09) during

95 Three donor ferrets infected with 2009 pandemic influenza A(H1N1) underwent daily quantitative

96 lpha-secreting CD8(+)CD69(+) T cells to 2009 pandemic influenza A(H1N1) upon vaccination in the 2010-

97 To evaluate whether pandemic influenza A(H1N1) vaccination in pregnancy incr

98 ects, HI antibody responses against the 2009 pandemic influenza A(H1N1) vaccine strain were significa

99 nctional antibody responses against the 2009 pandemic influenza A(H1N1) vaccine strain.

100 All donors had ADCC responses against 2009 pandemic influenza A(H1N1) virus (A[H1N1]pdm09) and avia

101 s season was characterized by a delayed 2009 pandemic influenza A(H1N1) virus (A[H1N1]pdm09) epidemic

102 3N2) virus infection (P = .002) but not 2009 pandemic influenza A(H1N1) virus (A[H1N1]pdm09) or influ

103 nfluenza season, nearly all circulating 2009 pandemic influenza A(H1N1) virus (A[H1N1]pdm09) strains

104 ring the 2013-2014 influenza season was 2009 pandemic influenza A(H1N1) virus (A[H1N1]pdm09).

105 he 2013-2014 influenza season, in which 2009 pandemic influenza A(H1N1) virus (influenza A[H1N1]pdm09

106 The admantane-resistant 2009 pandemic influenza A(H1N1) virus can develop the H275Y c

107 unit vaccine (ISV) targeting monovalent 2009 pandemic influenza A(H1N1) virus or live-attenuated infl

108 (H5N1) strain but comparable to that of 2009 pandemic influenza A(H1N1), based on the clinical signs,

109 Among patients with 2009 pandemic influenza A(H1N1), ratios for hIVIG (n = 9) ver

110 3N2) variant containing the M gene from 2009 pandemic influenza A(H1N1), termed "A(H3N2)vpM," to the

111 amma-secreting CD4(+)CD69(+) T cells to 2009 pandemic influenza A(H1N1).

112 intervals for influenza A(H3N2) (2.2 days), pandemic influenza A(H1N1)pdm09 (2.8 days), respiratory

113 e of patients acutely infected with the 2009 pandemic influenza A(H1N1)pdm09 virus (A[H1N1]pdm09) was

114 ly this method to a school-based outbreak of pandemic influenza A(H1N1)v that occurred in London, Uni

115 Low-dose priming with a mismatched pandemic influenza A(H5N1) vaccine would improve the rap

116 2009 pandemic influenza A/H1N1 (A(H1N1)pdm09) was first detec

117 re frequently in patients infected with 2009 pandemic influenza A/H1N1 strain (versus seasonal strain

118 epithelial cell cultures were infected with pandemic influenza A/H1N1 virus in vitro.

119 A small proportion (1%-1.5%) of 2009 pandemic influenza A/H1N1 virus strains (A[H1N1]pdm09) a

120 asonal influenza A/Panama/2007/99 (H3N2) and pandemic influenza A/Netherlands/602/2009 (H1N1) viruses

121 ommunity burden and severity of seasonal and pandemic influenza across different age groups and study

122 which corresponded to the timing of highest pandemic influenza activity.

123 ation was associated with protection against pandemic influenza and a reduction in hospital admission

124 lay in facilitating the geographic spread of pandemic influenza and highlight the need for further in

125 ped our understanding of the epidemiology of pandemic influenza and informs analysis of current and f

126 blic health practitioners commonly ask about pandemic influenza and match these with analytical metho

127 strain could also be useful in epidemic and pandemic influenza and should be considered for influenz

128 rovide reliable surveillance for seasonal or pandemic influenza and should be interpreted with cautio

129 onsidered a requirement for the emergence of pandemic influenza, and advanced knowledge of the molecu

130 , was antigenically similar to the 1918 H1N1 pandemic influenza, and consequently was considered to b

131 Seasonal and pandemic influenza are significant public health concern

132 pulation size changes, seasonal factors, and pandemic influenza, as appropriate.

133 ize the timing and intensity of seasonal and pandemic influenza at the national (United States), regi

134 Control of pandemic influenza by social-distancing measures, such a

135 The first pandemic influenza case detected by USAMRU-K surveillanc

136 e first wave and starting the second wave of pandemic influenza cases.

137 erved birth depressions were consistent with pandemic influenza causing first trimester miscarriages

138 ntibody against swine influenza A/H1N1(2009) pandemic influenza, children received 1 dose of 2010/201

139 Both seasonal and pandemic influenza continue to challenge both scientists

140 za vaccine that could diminish the threat of pandemic influenza disease and generally reduce the sign

141 Apart from the period of pandemic influenza due to influenza A virus subtype H1N1

142 to be demonstrated and, indeed, outbreaks of pandemic influenza during more humid spring, summer, and

143 Additionally, B cell responses to pandemic influenza H1N1 vaccination and infection in dif

144 des protection against the 2009 swine-origin pandemic influenza H1N1 virus (S-OIV) when carrying the

145 rom immunocompromised patients infected with pandemic influenza H1N1 were tested for viral fitness, p

146 Here we sequenced 153 pandemic influenza H1N1/09 virus genomes from United Kin

147 of individuals hospitalized with seasonal or pandemic influenza H1N1/09 viruses.

148 H1N1 pandemic influenza has been severe in children.

149 Pandemic influenza in 1918-19 killed more people than di

150 ients hospitalized with laboratory-confirmed pandemic influenza in 9 Influenza Hospitalization Survei

151 effective strategy for slowing the spread of pandemic influenza in countries with social contact netw

152 ern of infection during the epidemic of 2009 pandemic influenza in England is investigated here throu

153 In conclusion, the protracted spread of pandemic influenza in fall 2009 in the US was dominated

154 the geographic and temporal distribution of pandemic influenza in Kenya.

155 n of the first and second waves of 2009-2010 pandemic influenza in South Africa.

156 States; and 3) predict that a third wave of pandemic influenza in the winter or spring of 2010 was u

157 -protective antibodies against the 2009 H1N1 pandemic influenza, indicating antigenic similarities am

158 Relapses did not follow pandemic influenza infection.

159 as a risk factor for developing severe 2009 pandemic influenza infection.

160 Seasonal and pandemic influenza is a cause of morbidity and mortality

161 Pandemic influenza is a major public health concern, but

162 A key question in pandemic influenza is the relative roles of innate immun

163 tion of factors that drives the emergence of pandemic influenza is unclear, making it impossible to f

164 the morbidity and mortality associated with pandemic influenza isolates.

165 to better predict the impact of epidemic or pandemic influenza mitigation strategies.

166 important strategies to reduce the spread of pandemic influenza need public participation.

167 In the setting of limited resources, like in pandemic influenza, or with the potential limiting of re

168 HIV/AIDS, severe acute respiratory syndrome, pandemic influenza--originate in animals, are caused by

169 preparation is underway to mitigate the next pandemic influenza outbreak.

170 These findings suggest that the timing of pandemic influenza outbreaks is controlled by a combinat

171 y, are consistent with the general timing of pandemic influenza outbreaks observed for 2009 A/H1N1 in

172 Seasonal and pandemic influenza outbreaks remain a major human health

173 rains can be transmitted to humans and cause pandemic influenza outbreaks.

174 swabs, we tracked the course of seasonal and pandemic influenza over five successive cohorts (England

175 ine candidate expressing NA (PIV5-NA) from a pandemic influenza (pdmH1N1) virus or highly pathogenic

176 of NPIs during fall 2009 in response to H1N1 pandemic influenza (pH1N1) by New York City (NYC) public

177 Seasonal and especially pandemic influenza predispose patients to secondary bact

178 his Perspective focuses on the future of the Pandemic Influenza Preparedness (PIP) Framework, which w

179 International Health Regulations (2005), and Pandemic Influenza Preparedness Framework-strives for a

180 za pandemics to direct targeted research and pandemic influenza preparedness planning, emphasizing pr

181 should therefore be considered a priority in pandemic influenza preparedness planning.

182 finding could have important implications on pandemic influenza preparedness strategies.

183 been the focus of considerable investment in pandemic influenza preparedness.

184 erosol, which again heightens concerns about pandemic influenza preparedness.

185 t vaccination approach in young children for pandemic influenza preparedness.

186 The Pandemic Influenza Primary Care Reporting (PIPeR) cohort

187 ed in inter-pandemic seasons, the drivers of pandemic influenza remain debated.

188 Seasonal and pandemic influenza remains a constant threat.

189 Circulating levels of both seasonal and pandemic influenza require constant surveillance to ensu

190 Pandemic influenza requires interspecies transmission of

191 health care facilities against outbreaks of pandemic influenza requires pharmaceutical resources suc

192 potential from sequence data could transform pandemic influenza risk assessment capabilities.

193 te the fair sharing of public health-related pandemic influenza samples between countries.

194 ssion model to simulate a "mild-to-moderate" pandemic influenza scenario to estimate resource needs,

195 Protecting young children from pandemic influenza should also reduce transmission to su

196 er potential mutations may generate a future pandemic influenza strain that is oseltamivir-resistant,

197 be immediately mobilized upon infection with pandemic influenza strains derived from antigenic shift.

198 proteins are critical for the development of pandemic influenza strains from avian influenza viruses.

199 to study the transmissibility of potentially pandemic influenza strains.

200 ortant to continued surveillance against new pandemic influenza strains.

201 ntiviral compounds against both seasonal and pandemic influenza strains.

202 ies that protect against seasonal as well as pandemic influenza strains.

203 for absolute humidity in the transmission of pandemic influenza, such as 2009 A/H1N1, has yet to be d

204 an population to respond quickly to emerging pandemic influenza threats.

205 paradigms in disease, ranging from cancer to pandemic influenza to Alzheimer's disease.

206 These include the 2009-10 H1N1 pandemic influenza vaccination campaign, renewed attenti

207 uate the risk of foetal loss associated with pandemic influenza vaccination in pregnancy.

208 ion or nonadjuvanted whole-virion monovalent pandemic influenza vaccine and assessed the immunogenici

209 rther evaluated in a clinical trial as an H2 pandemic influenza vaccine candidate.

210 Three reassortant cold-adapted (ca) H2 pandemic influenza vaccine candidates with hemagglutinin

211 The 4-8-fold antigen-sparing adjuvanted pandemic influenza vaccine demonstrated superior and cli

212 e, developing novel adjuvants is crucial for pandemic influenza vaccine development.

213 e thus represents an advance in seasonal and pandemic influenza vaccine development.

214 en who previously received 2 doses of either pandemic influenza vaccine is safe and is immunogenic fo

215 evidence that 2 doses of AS03(B)-adjuvanted pandemic influenza vaccine may be sufficient to maintain

216 ith current technologies, to have sufficient pandemic influenza vaccine ready in time to impact the f

217 prospectively to rapidly assess seasonal and pandemic influenza vaccine safety.

218 uated different formulations of an H1N1 2009 pandemic influenza vaccine that deliver various viral he

219 vaccines, including oral cholera vaccine and pandemic influenza vaccine, have prompted discussion on

220 olepsy associated with a specific adjuvanted pandemic influenza vaccine.

221 As part of an efficacy trial of pandemic influenza vaccines (NCT01051661), RSV epidemiol

222 une responses provoked by H5N1 and 2009 H1N1 pandemic influenza vaccines after a single dose of intra

223 opment of neutralizing antibody responses to pandemic influenza vaccines and suggest that approaches

224 Since live attenuated pandemic influenza vaccines may potentially express a he

225 It is essential to develop candidate pandemic influenza vaccines that are safe and effective

226 Using seasonal and pandemic influenza vaccines, we document profound differ

227 o response to vaccine when evaluating future pandemic influenza vaccines.

228 nation inhibition (HI) antibody responses to pandemic influenza vaccines.

229 aminidase (NA) antibody titers to 2009(H1N1) pandemic influenza virus (pH1N1) correlated with titers

230 The 2009 pandemic influenza virus (pH1N1) is a swine-origin reass

231 influenza A viruses, which includes the 2009 pandemic influenza virus A/H1N1/2009, highly pathogenic

232 E227A in the hemagglutinin (HA) of the 2009 pandemic influenza virus alter its pathogenesis and tran

233 ike previous pandemic viruses, the 2009 H1N1 pandemic influenza virus does not code for the virulence

234 Although most people infected with the 2009 pandemic influenza virus had mild or unapparent symptoms

235 weakened cytokine responses to the 2009 H1N1 pandemic influenza virus in human cells.

236 demiological patterns of successive waves of pandemic influenza virus in humans has been documented t

237 genic avian influenza (HPAI) and of the 1918 pandemic influenza virus in humans remain poorly underst

238 n these studies, we examined the severity of pandemic influenza virus in obese mice and evaluated ant

239 ortality burden associated with seasonal and pandemic influenza virus infection among pregnant women

240 Pandemic influenza virus infection in pregnancy was asso

241 epigenetic factors on host susceptibility to pandemic influenza virus infection.

242 lung tissues specific to 1918 or 2009 human pandemic influenza virus infections.

243 ogenic avian influenza virus (HPAI) and 1918 pandemic influenza virus remain poorly understood.

244 The 2009 H1N1 pandemic influenza virus represents the greatest inciden

245 emergence and rapid spread of the 2009 H1N1 pandemic influenza virus showed that many diagnostic tes

246 errets following intranasal infection with a pandemic influenza virus strain (A/California/4/09 [CA09

247 le with multiple gene segments from the 2009 pandemic influenza virus strain without prior adaptation

248 ction with drifted seasonal as well as novel pandemic influenza virus strains therefore obviating the

249 H5N1 avian, H1N1 seasonal, and H1N1 2009 pandemic influenza virus strains were compared by infect

250 , and recognize determinants in seasonal and pandemic influenza virus strains.

251 dly reactive and can neutralize seasonal and pandemic influenza virus strains.

252 and can be easily upscaled in response to a pandemic influenza virus threat.

253 influenza vaccines that can control emerging pandemic influenza virus threats without the need to gen

254 The rapid dissemination of the 2009 pandemic influenza virus underscores the need for univer

255 The development of an H2 pandemic influenza virus vaccine candidate should theref

256 We conclude that live attenuated pandemic influenza virus vaccines replicate similarly in

257 idates for development as live attenuated H2 pandemic influenza virus vaccines.

258 of vaccine candidates for the production of pandemic influenza virus vaccines.

259 The 1918 pandemic influenza virus was the most devastating infect

260 rotein might have in the context of the 2009 pandemic influenza virus, A/California/04/2009 (Cal/09).

261 HA protein is central to the emergence of a pandemic influenza virus, its required molecular propert

262 differ only a few amino acids from the 1918 pandemic influenza virus, suggesting that 1918-like pand

263 is review, we discuss the origin of the 1918 pandemic influenza virus, the pandemic's unusual epidemi

264 rix (M) gene from the Influenza A(H1N1)pdm09 pandemic influenza virus.

265 with great potential for the emergence of a pandemic influenza virus.

266 igenically similar to the swine lineage 2009 pandemic influenza virus.

267 ) infected with the fully reconstructed 1918 pandemic influenza virus.

268 ertain individuals infected with the emerged pandemic influenza virus.

269 inin protein sequence homology with the 1918 pandemic influenza virus.

270 enza virus sharing high homology to the 1918 pandemic influenza virus.

271 CC antibodies may enhance protection against pandemic influenza virus.

272 s a major virulence determinant for the 1918 pandemic influenza virus; however, it encodes no known v

273 tween prior exposures to seasonal and recent pandemic influenza viruses and the development of hetero

274 creased genetic sequencing of African A/H1N1 pandemic influenza viruses during 2009-2013 revealed mul

275 Pandemic influenza viruses have consistently higher atta

276 After the emergence of pandemic influenza viruses in 1957, 1968, and 2009, exis

277 nants of the host range and pathogenicity of pandemic influenza viruses in mammals.

278 bute to the optimal competitive advantage of pandemic influenza viruses in mice.

279 que antivirals for treatment of seasonal and pandemic influenza viruses is warranted.

280 Pandemic influenza viruses modulate proinflammatory resp

281 ation today, and in particular, seasonal and pandemic influenza viruses pose a persistent threat to p

282 The emergence of pandemic influenza viruses poses a major public health t

283 In addition to seasonal infections, emerging pandemic influenza viruses present a continued threat to

284 rstand the pathogenicity and transmission of pandemic influenza viruses so that we may develop improv

285 These results show how pandemic influenza viruses subvert the immune response.

286 ors of virulence linked to highly pathogenic pandemic influenza viruses without amplification or labe

287 disease in swine infected with seasonal and pandemic influenza viruses, and leads to the suggestion

288 tiviral resistance emergence in seasonal and pandemic influenza viruses, especially in seriously ill

289 virulence, and pathogenic properties of past pandemic influenza viruses, including the 1918 virus, is

290 ctly chart the evolutionary history of human pandemic influenza viruses, which originated in animal h

291 ith increased virulence in highly pathogenic pandemic influenza viruses.

292 uperior protective adaptive immunity against pandemic influenza viruses.

293 r understanding the origins and evolution of pandemic influenza viruses.

294 -reactive T cells provide protection against pandemic influenza viruses.

295 rotecting against existing or newly emerging pandemic influenza viruses.

296 into viral fitness and the emergence of new pandemic influenza viruses.

297 romising new approach for protection against pandemic influenza viruses.

298 stering 2 separate vaccines for seasonal and pandemic influenza was necessary in 2009.

299 s matched geographical patterns for the fall pandemic influenza wave.

300 ssociated with those gaps, for responding to pandemic influenza within and between six territories in